Are these 3 AIM-listed biotechnology stocks a good buy?

3 min read | November 10, 2021 12:17 AM AEDT | By Sreenivas D Ajankar

Are these 3 AIM-listed biotechnology stocks a good buy? — Image source: Guy Shapira, Shutterstock.com

Genedrive Plc (LON:GDR)

FTSE AIM-listed company operates as a molecular diagnostics company providing a diagnostics platform for contagious diseases and pathogen detection. The platform provided by the company is low cost, simple to use and provide a robust diagnosis.

For the financial year ended 30 June 2021, the company reported revenue of £0.7 million, while its loss for the financial year was £0.69 million. The company is currently in the growth stage of the business cycle, where it is exploring different therapies and treatments through clinical trials and is likely to launch two new products based on the point of care (POC) diagnostic. Two products are Antibiotic Induced Hearing Loss for newborn children and a high throughput test for Covid-19, which is designed to use on a third-party machine. The launch of these products might help boost the company’s revenue and profitability.

Genedrive Plc currently trades at GBX 18.85, down by 1.82% on 09 November 2021 at 10:32 am GMT+1 with a market cap of £17.62 million.

ImmuPharma Plc (LON: IMM)

The company is engaged in the research and development of peptide-based therapeutics used to treat metabolic diseases, cancer, and other autoimmune diseases.

The company’s leading project is Lupuzor™ which is used to treat lupus and other autoimmune diseases. It is currently undergoing a clinical trial and has signed an agreement with Avion Pharmaceuticals for exclusive Trademark and development of Lupuzor™. Both companies are working closely on the clinical trials, with Avion Pharmaceuticals agreeing to fund a new international phase 3 trial and launch its product in the US market. ImmuPharma Plc is also carrying out research and development of other drugs and reported R&D expenditure of £1.3 million, while its loss was at £3.7 million for the six months ended 30 June 2021.

ImmuPharma Plc currently trades at GBX 7.20, up by 7.46% on 09 November 2021 at 10:32 am GMT+1 with a market cap of £16.76 million.

Ergomed Plc (LON: ERGO)

The company provides clinical trials planning and other services to its clients from the pharmaceutical sector. It also offers medical information services, management, and drug safety.

The company reported robust performance in the first six months of 2021. It reported a 38.8% rise in revenue at £56 million, while its gross profit rose by 24.3% at £23 million during the period. Higher revenue was attributed to growth in service fees revenue. Also, the company continue to expand its presence in the international market. The increase in revenue and profitability is expected to continue in upcoming quarters, driven by the growth in the order book. The company’s future contracted order book stands at £227.8 million as of 30 June 2021.

Ergomed Plc currently trades at GBX 1,465, down by 0.34% on 09 November 2021 at 10:32 am GMT+1 with a market cap of £722.02 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.